Acquired resistance to TKIs in solid tumours: learning from lung cancer

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

(2014) H. A. Yu et al.   ANNALS OF ONCOLOGY

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer

(2013) Eiko Theodora Browning et al.   Journal of Thoracic Oncology

Taking Aim at ALK Across the Blood–Brain Barrier

(2013) D. Ross Camidge   Journal of Thoracic Oncology

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

(2013) Soyeon Kim et al.   Journal of Thoracic Oncology

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2013) Helena A. Yu et al.   Journal of Thoracic Oncology

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group

(2013) Nancy U Lin et al.   LANCET ONCOLOGY

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

(2013) Steven J. Bowlin et al.   MAYO CLINIC PROCEEDINGS

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

(2013) K E Ware et al.   Oncogenesis

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

(2012) Y. Y. Janjigian et al.   ANNALS OF ONCOLOGY

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

(2012) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

(2012) Seiji Yano et al.   CANCER SCIENCE

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge

(2012) Seema Nagpal et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer WithEGFRMutations

(2012) Teresa Moran et al.   JOURNAL OF CLINICAL ONCOLOGY

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

(2012) Jasmine Foo et al.   Journal of Thoracic Oncology

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib

(2012) Oliver Gautschi et al.   Journal of Thoracic Oncology

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

(2012) Andrew J. Weickhardt et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

(2011) J. E. Chaft et al.   CLINICAL CANCER RESEARCH

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

(2011) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

(2011) C. Grommes et al.   NEURO-ONCOLOGY

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

(2011) Chenguang Li et al.   PLoS One

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors

(2011) A. C. Faber et al.   Cancer Discovery

Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

(2010) S. Heon et al.   CLINICAL CANCER RESEARCH

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

(2010) Wee-Lee Yeo et al.   Journal of Thoracic Oncology

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer

(2009) Alessandra Bearz et al.   LUNG CANCER

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations

(2008) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

(2008) N. Godin-Heymann et al.   MOLECULAR CANCER THERAPEUTICS

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA